source
- PepGen soars on promising early data for muscular dystrophy drugWhile from a small study, the findings suggest PepGen’s therapy compares favorably to other RNA-based medicines in testing at Novartis and Dyne Therapeutics.BioPharma Dive · 9d ago↗ source
- STAT+: GLP-1s are given an FDA warning for rare eye condition riskThe FDA warned that GLP-1 drugs carry a potential risk of a rare but serious eye condition sometimes referred to as an “eye stroke.”STAT · 10d ago↗ source
- Recon: Bayer wins FDA approval for stroke prevention drug; Third Rock enters $2B partnership with AI-focused Chinese biotechWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 10d ago↗ source